NASDAQ:BCRX
BioCryst Pharmaceuticals Stock News
$5.34
+0.240 (+4.71%)
At Close: May 09, 2024
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
06:47pm, Monday, 06'th May 2024
The company unveiled its first-quarter earnings that morning. It notched convincing beats on both the top and bottom lines.
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript
11:42am, Monday, 06'th May 2024
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q1 2024 Earnings Call Transcript May 6, 2024 8:30 AM ET Company Participants John Bluth - IR Jon Stonehouse - CEO Charlie Gayer - CCO Helen Thackray - Chi
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
09:11am, Monday, 06'th May 2024
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.28 per share a year ago.
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Monday, 29'th Apr 2024
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Monday, 25'th Mar 2024
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmu
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
08:29am, Friday, 01'st Mar 2024
Each of these hidden penny stock gems have the potential to provide triple digit growth to investors. Investors are forever on the lookout for Investments that can turn $1 into $2 or more.
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
09:11am, Monday, 26'th Feb 2024
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.38 per share a year ago.
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Wednesday, 21'st Feb 2024
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the TD Cowen 44th Annual Health Care Con
RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of r
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
10:31am, Tuesday, 09'th Jan 2024
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely
06:34pm, Thursday, 14'th Dec 2023
BioCryst Pharmaceuticals, Inc. proof-of-concept data from a phase 1 study, using BCX10013 for the treatment of patients with complement-mediated disorders, is expected in 2024. Oral C2, C5, and Bifunc
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Tuesday, 21'st Nov 2023
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6th Annual Evercore ISI HealthCONx C
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO�
BioCryst to Report Third Quarter 2023 Financial Results on November 2
07:00am, Thursday, 19'th Oct 2023
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?
11:18am, Tuesday, 19'th Sep 2023
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in